Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin plus nab-paclitaxel for advanced thymic epithelial tumors (Nab-TET)
jRCTs071240019Phase 2Recruiting
- Start
- Jul 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin and paclitaxel in thymoma, thymic carcinoma (TC) and thymic malignancies (TET). Primary endpoint: Overall response proportion (ORP) for thymic epithelial tumor. Started Jul 2024; status: recruiting.
02
Drugs
carboplatinpaclitaxel
03
Conditions
thymomathymic carcinoma (TC)thymic malignancies (TET)
Beyond the preview
Go deeper on jRCTs071240019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071240019.